Literature DB >> 3312029

[Results of several different controlled studies with ceftazidime in the treatment of infections in immunosuppressed patients].

B E de Pauw1.   

Abstract

At our Division of Hematology eight clinical studies were performed using ceftazidime alone or in combination with other antibiotics. In the first randomised study ceftazidime (45 patients) proved to be statistically superior (p less than or equal to 0.05) to the combination of cefotaxime and gentamicin (45 patients). The poor results of the latter combination - 49% clinical responses compared with 71% for ceftazidime - have been confirmed by the EORTC study group of Klastersky (1). The second study aimed at 30 patients who failed to respond to cefotaxime and gentamicin. All bacteriologically documented infections were cured with ceftazidime. The clinical response rate was 73%. In the third randomised study we compared ceftazidime plus flucloxacillin in 49 patients in order to extend the spectrum to resistant staphylococci with a ceftazidime monotherapy (51 patients). The addition of flucloxacillin did not improve the results substantially. The overall clinical response rate was 81% with the combination and 85% with ceftazidime alone. In the fourth study on 23 patients with allogenic bone marrow transplantations, receiving cyclosporin A as prophylaxis against graft versus host disease, no nephrotoxic effect was observed. The fifth study comprised 20 patients over 65 years of age, in whom no toxicity different from younger patients was seen. In the sixth study with 51 patients per group we compared ceftazidime with the combination ceftazidime plus cephalothin. This study demonstrated an increased efficacy of the combination against Staphylococcus epidermidis and proved that two different cephalosporins, given simultaneously, are not antagonistic. Analysis of 34 Pseudomonas septicaemias in the seventh study with a clinical success rate of 94% demonstrated clearly the potency of ceftazidime against this particularly dangerous organism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312029     DOI: 10.1007/BF01645864

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

Review 1.  Empiric antibiotic therapy.

Authors:  S C Schimpff; J Aisner
Journal:  Cancer Treat Rep       Date:  1978-05

2.  Treatment of Pseudomonas aeruginosa septicemia in neutropenic patients with ceftazidime.

Authors:  B E de Pauw; T de Witte; J T Janssen; C Haanen
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

3.  A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  B de Pauw; K Williams; J de Neeff; T Bothof; T de Witte; R Holdrinet; C Haanen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

4.  Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients.

Authors:  B E de Pauw; F Kauw; H Muytjens; K J Williams; T Bothof
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

5.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

6.  Can the third-generation cephalosporins eliminate the need for antimicrobial combinations?

Authors:  R C Moellering
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

7.  Approaching the controversies in antibacterial management of cancer patients.

Authors:  P A Pizzo; J Commers; D Cotton; J Gress; J Hathorn; J Hiemenz; D Longo; D Marshall; K J Robichaud
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

Review 8.  Limitations of current antimicrobial therapy in the immunosuppressed host: looking at both sides of the coin.

Authors:  P A Pizzo; L S Young
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

Review 9.  Empiric treatment of infections in neutropenic patients with cancer.

Authors:  J Klastersky
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Ceftazidime as first-line therapy for fever in acute leukaemia.

Authors:  J P Donnelly; R E Marcus; J M Goldman; J Cohen; A M Worsley; D Catovsky; J H Darrell; S V Want; D A Galton
Journal:  J Infect       Date:  1985-11       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.